-

OI Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into O-I Glass (OI)

O-I Glass guided full-year 2026 adjusted earnings of $1.65 to $1.90 per share on February 11, 2026. Q2 2026 adjusted EPS came in at $0.09, and management slashed that guidance for the second time in two quarters.

NEW YORK--(BUSINESS WIRE)--Guidance of $1.65 to $1.90 per share. Actual Q1 2026 adjusted EPS was $0.05 and earnings guidance was reduced to $1.00 - $1.50 per share. Actual Q2 2026 adjusted EPS was $0.09. O-I Glass (NYSE: OI) shares fell approximately 15% on July 29, 2026 after the Company reported second quarter results and cut its full-year outlook. If you lost money on OI shares, you are encouraged to submit your loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

On the April 29, 2026 first quarter earnings call, Chief Executive Officer Gordon Hardie told investors, "We have updated our 2026 guidance to adjusted earnings of $1 to $1.50 per share." On the same call, Mr. Hardie stated, "We expect full-year sales volumes to be about flat with the prior year," and said the Company was "confident we can strengthen results as the year progresses."

Three months later, the Company reported adjusted EPS of $0.09 for the second quarter, missed revenue expectations, and reduced its full-year guidance. Europe segment operating profit was reported at $6 million, compared with $90 million a year earlier. On the April 29 call, the Europe decline had been described as "down roughly $68 million from a year ago." The investigation concerns whether O-I Glass may not have adequately disclosed the condition of its European operations at the time those forward-looking figures were given.

Shareholders who purchased O-I Glass stock and suffered losses may have their claim evaluated at no cost, or call (212) 363-7500.

WHY LEVI & KORSINSKY -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

Frequently Asked Questions About the OI Investigation

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether O-I Glass made materially false or misleading statements regarding its full-year 2026 guidance and projected fiscal 2027 targets. When O-I Glass lowered its guidance following Q2 2026 results, the stock declined sharply.

Q: How much did OI stock drop? A: Shares fell approximately 15% on July 29, 2026 after the Company again reduced its full-year 2026 guidance and further pushed back planned fiscal 2027 targets. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek recovery.

Q: Who is eligible to participate in the OI investigation? A: Investors who purchased O-I Glass stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do OI investors need to do right now? A: Gather brokerage records showing purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500.

Q: What is a lead plaintiff and why does it matter? A: If the investigation proceeds to legal action, a lead plaintiff is the investor a court appoints to represent affected investors, typically the investor with the largest documented losses. Contacting the firm during the investigation phase preserves that option.

Q: What if I already sold my OI shares -- can I still recover losses? A: Yes. Eligibility depends on when you purchased, not whether you still hold the shares. Investors who bought OI and sold at a loss may still participate.

Q: What does it cost me to participate? A: There is no upfront cost. These matters are generally handled on a contingency basis -- no retainer and no out-of-pocket costs.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions.

Attorney Advertising. Prior results do not guarantee similar outcomes.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Levi & Korsinsky, LLP

NYSE:OI

Release Versions

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

More News From Levi & Korsinsky, LLP

PSN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Parsons Corporation (PSN)

NEW YORK--(BUSINESS WIRE)--Parsons Corporation (NYSE: PSN) reported a net loss of $15 million, a $70 million year-over-year reduction; shares fell 35%. If you lost money on Parsons stock, click here to submit your loss information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.When Parsons reported its Q1 results on April 29, 2026, it reaffirmed previous guidance on the back of a net income of $53 million, a reduced performance o...

PHAT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Phathom Pharmaceuticals, Inc. (PHAT)

NEW YORK--(BUSINESS WIRE)--Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) shareholders took losses after the Company lowered its full-year 2026 revenue guidance to $310 million–$325 million from its previously issued $320 million–$345 million range, falling below Wall Street consensus estimates of approximately $332 million. If you suffered a loss on your Phathom Pharmaceuticals investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via...

CAPR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Capricor (CAPR)

NEW YORK--(BUSINESS WIRE)--Capricor (NASDAQ: CAPR) shares collapsed 60% to 70% on July 27, 2026 after FDA staff briefing documents raised significant concerns regarding the evidence supporting Deramiocel's efficacy ahead of the July 29, 2026 advisory committee meeting. CAPR shareholders who saw their investment drop after the FDA briefing documents are encouraged to act promptly. To respond while the investigation is active, submit your CAPR loss information or contact Levi & Korsinsky, LLP...
Back to Newsroom